|
|
 Previous Article | Table of Contents | Next Article 
Multiple myeloma: significance of plasmablastic subtype in morphological
classification
PR Greipp, NM Raymond, RA Kyle and WM O'Fallon
We classified 100 cases of myeloma before chemotherapy as mature (28),
intermediate (38), immature (19), or plasmablastic (15). The plasmablastic
group had an estimated median survival (Kaplan-Meier method) of ten months,
compared to 35 months for the other types (P less than .05). Decreased
survival in the plasmablastic group was due to more frequent deaths in the
first six months. There were no significant differences in survival among
the mature, intermediate, and immature groups or among patients with
different morphological grade or asynchrony scores. The plasmablastic
myeloma group had more frequent renal insufficiency and higher plasma cell
labeling indices, which may have contributed to the shorter survival.
Volume 65,
Issue 2,
pp. 305-310,
02/01/1985
Copyright © 1985 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. J. Mellor, S. Haugland, K. C. Smith, R. M. Powell, J. Archer, T. J. Scase, E. J. Villiers, P. E. McNeil, C. Nixon, C. Knott, et al.
Histopathologic, Immunohistochemical, and Cytologic Analysis of Feline Myeloma-Related Disorders: Further Evidence for Primary Extramedullary Development in the Cat
Vet. Pathol.,
March 1, 2008;
45(2):
159 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-F. Qi, J. X. Zhou, C. H. Lee, Z. Naghashfar, S. Xiang, A. L. Kovalchuk, T. N. Fredrickson, J. W. Hartley, D. C. Roopenian, W. F. Davidson, et al.
Anaplastic, Plasmablastic, and Plasmacytic Plasmacytomas of Mice: Relationships to Human Plasma Cell Neoplasms and Late-Stage Differentiation of Normal B Cells
Cancer Res.,
March 15, 2007;
67(6):
2439 - 2447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Robillard, H. Avet-Loiseau, R. Garand, P. Moreau, D. Pineau, M.-J. Rapp, J.-L. Harousseau, and R. Bataille
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
Blood,
August 1, 2003;
102(3):
1070 - 1071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Konigsberg, N. Zojer, J. Ackermann, E. Kromer, H. Kittler, E. Fritz, H. Kaufmann, T. Nosslinger, L. Riedl, H. Gisslinger, et al.
Predictive Role of Interphase Cytogenetics for Survival of Patients With Multiple Myeloma
J. Clin. Oncol.,
February 14, 2000;
18(4):
804 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar, R. Fonseca, M. Q. Lacy, T. E. Witzig, T. M. Therneau, R. A. Kyle, M. R. Litzow, M. A. Gertz, and P. R. Greipp
Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma
J. Clin. Oncol.,
May 1, 1999;
17(5):
1551 - 1551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, S. Jagannath, K.R. Desikan, S. Mattox, D. Vesole, D. Siegel, G. Tricot, N. Munshi, A. Fassas, S. Singhal, et al.
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Blood,
January 1, 1999;
93(1):
55 - 65.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Greipp, T. Leong, J. M. Bennett, J. P. Gaillard, B. Klein, J. A. Stewart, M. M. Oken, N. E. Kay, B. Van Ness, and R. A. Kyle
Plasmablastic Morphology---An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group
Blood,
April 1, 1998;
91(7):
2501 - 2507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bataille and J.-L. Harousseau
Multiple Myeloma
N. Engl. J. Med.,
June 5, 1997;
336(23):
1657 - 1664.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, S. Jagannath, D. H. Vesole, S. Naucke, B. Cheson, S. Mattox, D. Bracy, S. Salmon, J. Jacobson, J. Crowley, et al.
Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma
Blood,
February 1, 1997;
89(3):
789 - 793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
